Investing.com -- Moderna Inc (NASDAQ:MRNA) stock fell 5.5% and Pfizer Inc (NYSE:PFE) shares dropped 2.6% following reports from Newsweek and The Daily Beast that the Trump administration may be ...

The landscape of COVID-19 vaccinations for children is shifting in the US. How will this affect the upcoming virus season?

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

The Trump administration will move to pull the COVID vaccine off the U.S. market “within months,” one of Robert F. Kennedy Jr ...

Those with private health insurance expected to have an easier time getting vaccines than those on Medi-Cal if CDC changes ...

Among people ages 65 to 85, the Pfizer data suggest that antibody levels against the delta variant after receiving a third dose of vaccine are greater than 11-fold than following a second dose.

The Pfizer vaccine is the first to receive FDA approval, while the Moderna and Johnson & Johnson vaccines are available under an emergency use authorization. For children ages 12 to 15, Pfizer's ...

Pfizer's early data has spotlighted the future of COVID-19 vaccine distribution, particularly because the company's vaccine presents a potential hurdle: It needs to be stored at around -70 degrees ...

A syringe is prepared with the Pfizer COVID-19 vaccine at a vaccination clinic in Chester, Pa., on Dec. 15, 2021. Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is ...

Pfizer is the first of several companies to report results from ongoing late-stage trials. Moderna, another company in the race for a vaccine, launched a trial on July 27 -- the same day as Pfizer.

Pfizer’s clinical trials in children 5 to 11 did not measure the vaccine’s effectiveness against COVID-19. Effectiveness was “never the intended primary endpoint,” Anderson said.